Kyverna Therapeutics (NASDAQ:KYTX) Sees Large Volume Increase

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) shares saw strong trading volume on Thursday . 292,793 shares traded hands during trading, a decline of 22% from the previous session’s volume of 377,592 shares.The stock last traded at $19.60 and had previously closed at $20.43.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Leerink Partnrs reaffirmed an “outperform” rating on shares of Kyverna Therapeutics in a research report on Monday, March 4th. JPMorgan Chase & Co. assumed coverage on shares of Kyverna Therapeutics in a research report on Monday, March 4th. They issued an “overweight” rating and a $39.00 target price for the company. SVB Leerink started coverage on Kyverna Therapeutics in a report on Monday, March 4th. They set an “outperform” rating and a $48.00 price target on the stock. Morgan Stanley started coverage on Kyverna Therapeutics in a report on Monday, March 4th. They issued an “overweight” rating and a $40.00 price objective for the company. Finally, Wells Fargo & Company began coverage on Kyverna Therapeutics in a research note on Monday, March 4th. They set an “overweight” rating and a $44.00 target price on the stock. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $42.75.

Kyverna Therapeutics Stock Performance

The company’s fifty day moving average is $26.10.

Insider Buying and Selling at Kyverna Therapeutics

In other news, major shareholder Northpond Ventures Iii Gp, Llc acquired 450,000 shares of the company’s stock in a transaction dated Monday, February 12th. The shares were bought at an average price of $22.00 per share, with a total value of $9,900,000.00. Following the purchase, the insider now owns 450,000 shares of the company’s stock, valued at $9,900,000. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.